ArchiveAugust 2018

Treatment of Progressive MS, A new era dawns

A comment yesterday said “Come on, give us something to help us get out of bed in the morning, something to slow down the progression to social isolation and total disability” News for the US has surfaced that says we are on the way. This is a repeat trial but this time in seondary progressive MS. This repeats what was found in relapsing remitting disease. This study shows that brain...

Do MS drugs stop the development of SPMS?

You asked what ProfG thinks of this paper. To answer that question I don’t think much Paper Coret F, Pérez-Miralles FC, Gascón F, Alcalá C, Navarré A, Bernad A, Boscá I, Escutia M, Gil-Perotin S, Casanova B. Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783347...

Will They, Won’t They

  Following the approval of ocrelizumab for progressive MS, it stands to reason that alemtuzumab will also be similarly active However, the tortoise is yet to set off and the Hare has crossed the finished line. So should the tortoise start the race? This is the dilema for Sanofi Genzyme and whether they should do a progressive MS trial.Of the highly active treatments it has the most liberal...

Grey matter brain loss in MS

Brain. 2018 Jun; 141(6): 1665–1677. Published online 2018 May 8. doi: 10.1093/brain/awy088 Progression of regional grey matter atrophy in multiple sclerosis Arman Eshaghi, Razvan V Marinescu, Alexandra L Young, Nicholas C Firth, Ferran Prados, M Jorge Cardoso, Carmen Tur, Floriana De Angelis, Niamh Cawley, Wallace J Brownlee, Nicola De Stefano, M Laura Stromillo, Marco Battaglini, Serena...

Off-label or branded up?

MS is big business and it looks like it is set to continue for some time yet, thanks to the lawyers. ProfG suggested on Twitter that people “view off-label as a second-class choice” and prefer to go with “licensed innovator formulations.” He said “branding and status is important in healthcare”. Maybe true if you can afford it, but access to effective treatment...

Walking, or Running, the Talk – ProfG does it

Regular exercise is good for you. Two week’s ago I did a post on setting up a national challenge on using the parkrun platform to raise awareness about exercise and to get the MS community behind exercise. The following are the results of the survey you completed. The results are self-evident; we need to make this happen.  I am smitten by #Run4MS as the proposed name for the...

Mark’s post: Measuring fatigue in MS

  Fatigue is complicated and multifactorial. It may be classified as: Primary fatigue  Primary fatigue is apparently directly related to neurological damage, affecting one’s ability to activate or control muscle groups. It commonly affects walking.    This is where damage to the central nervous system directly contributes to physical disability and means that the person affected must...

Should we be ignored, disproved or whitewashed? Autoimmunity after alemtuzumab

Last year we suggested that a problem with alemtuzumab was that it failed to adequately deplete immature B cells in the bone marrow. These cells rapidly re-populate the body after depletion and this leads to a hyper-repopulation of B cells. Importantly, and different from ocrelizumab and cladribine, which both deplete B cells, this occurs after alemtuzumab in the relative absence of T cell...

DIY SlideShare site

Dear Blog Reader I must apologise; my SlideShare site has been disabled by LinkedIn. I have been told that many of my slides include copyrighted material. Strictly speaking, this is correct. However, LinkedIn doesn’t understand that academics often use each other’s materials for teaching/academic purposes without getting specific agreements in place to address copyright issues. I...

The New MS Subtype. Is ProfG Wrong to Suggest MS is a Single Entity? Is MS just more like EAE?

Yesterday it seemed to me that we had someone who was making a comment and was rubbing their hands with glee (gloating) to suggest that BartsMS was wrong.  I am sure we are wrong many times and anyone reading the blog regularly will note that we are humble enough to accept our mistakes.  Likewise, the tone of a different comment, seemed to me, to be a complaint that “you”...

Translate

Categories

Recent Posts

Recent Comments

Archives